- Home
- TLSI vs KPTI Comparison
TLSI vs KPTI Comparison
Compare TLSI & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSI
- KPTI
- Stock Information
- Founded
- TLSI 2010
- KPTI 2008
- Country
- TLSI United States
- KPTI United States
- Employees
- TLSI N/A
- KPTI N/A
- Industry
- TLSI Medical Specialities
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- TLSI Health Care
- KPTI Health Care
- Exchange
- TLSI Nasdaq
- KPTI Nasdaq
- Market Cap
- TLSI 124.9M
- KPTI 103.5M
- IPO Year
- TLSI N/A
- KPTI 2013
- Fundamental
- Price
- TLSI $3.95
- KPTI $0.66
- Analyst Decision
- TLSI Strong Buy
- KPTI Strong Buy
- Analyst Count
- TLSI 6
- KPTI 4
- Target Price
- TLSI $11.75
- KPTI $5.00
- AVG Volume (30 Days)
- TLSI 52.7K
- KPTI 859.4K
- Earning Date
- TLSI 11-14-2024
- KPTI 11-05-2024
- Dividend Yield
- TLSI N/A
- KPTI N/A
- EPS Growth
- TLSI N/A
- KPTI N/A
- EPS
- TLSI N/A
- KPTI N/A
- Revenue
- TLSI $26,891,000.00
- KPTI $148,442,000.00
- Revenue This Year
- TLSI $60.97
- KPTI $6.67
- Revenue Next Year
- TLSI $53.69
- KPTI $8.58
- P/E Ratio
- TLSI N/A
- KPTI N/A
- Revenue Growth
- TLSI 67.90
- KPTI 1.77
- 52 Week Low
- TLSI $3.50
- KPTI $0.65
- 52 Week High
- TLSI $10.42
- KPTI $1.95
- Technical
- Relative Strength Index (RSI)
- TLSI 46.18
- KPTI 29.10
- Support Level
- TLSI $3.76
- KPTI $0.65
- Resistance Level
- TLSI $4.17
- KPTI $0.83
- Average True Range (ATR)
- TLSI 0.35
- KPTI 0.04
- MACD
- TLSI -0.04
- KPTI -0.01
- Stochastic Oscillator
- TLSI 33.66
- KPTI 8.70
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.